4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates

4D Molecular Therapeutics (FDMT) reported a Q2 2025 loss of $0.98 per share, wider than the Zacks Consensus Estimate of a $0.88 loss, and revenues of $0.02 million, missing estimates by 98.58%. This marks the fourth consecutive quarter FDMT has failed to surpass consensus EPS estimates, contributing to its year-to-date underperformance against the S&P 500. Despite these misses, the stock retains a Zacks Rank #2 (Buy) based on favorable estimate revisions prior to the earnings release, suggesting potential for near-term market outperformance.

Analysis

4D Molecular Therapeutics (FDMT) reported a significant operational miss for the quarter ended June 2025, with a loss per share of $0.98 against a consensus estimate of $0.88. This loss is also wider than the $0.63 loss reported in the prior-year period. The revenue figure was particularly weak, coming in at just $0.02 million, a 98.58% miss versus consensus, even though it represents an increase from zero revenue a year ago. This marks the fourth consecutive quarter in which the company has failed to surpass consensus EPS estimates, establishing a pattern of under-delivery. This fundamental weakness is reflected in the stock's performance, with a mere 1.1% year-to-date gain, substantially lagging the S&P 500's 8.6% advance. A key point of dissonance is the stock's Zacks Rank #2 (Buy), which was based on a favorable trend in estimate revisions *prior* to this disappointing release. The outlook is now highly dependent on management's commentary, which will be critical in determining if future consensus estimates, currently at a loss of $0.93 for the next quarter, will be revised downward.

Key Decisions for Investors

• Investors should treat the pre-existing Zacks #2 (Buy) rating with extreme caution, as it was based on data preceding the significant Q2 earnings and revenue miss.
• The primary focus should be on management's commentary during the earnings call to understand the drivers of the massive revenue shortfall and to gauge the credibility of future growth projections.
• Given the consistent failure to meet consensus estimates and significant stock underperformance versus the S&P 500, re-evaluating any long positions is prudent until there is clear evidence of a turnaround in execution.